Invivyd (IVVD) Net Shares Issued and Repurchased (2021 - 2025)
Invivyd's (IVVD) quarterly Net Shares Issued and Repurchased came in at $12.2 million in Q4 2025, down 14.47% on a YoY basis from $14.2 million in Q4 2024, and up 31.67% quarter-over-quarter from $9.2 million in Q1 2025.
Analysis
Invivyd (IVVD) Net Shares Issued and Repurchased (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Net Shares Issued and Repurchased for 5 consecutive years, with $12.2 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Shares Issued and Repurchased fell 14.47% year-over-year to $12.2 million; the trailing twelve-month figure through Dec 2025 stood at $12.2 million (down 14.47% YoY), and the FY2025 full-year result was $12.2 million, down 14.47% from the prior year.
- Net Shares Issued and Repurchased improved to $12.2 million in Q4 2025 per IVVD's latest filing, from $9.2 million in the prior quarter.
- Across five years, Net Shares Issued and Repurchased topped out at $16.2 million in Q4 2021 and bottomed at $3.1 million in Q1 2023.
- Historically, Net Shares Issued and Repurchased has averaged $9.6 million across 5 years, with a median of $9.9 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Net Shares Issued and Repurchased sank 44.48% in 2023, then soared 153.39% in 2025.
- Over 5 years, Net Shares Issued and Repurchased stood at $16.2 million in 2021, then slipped by 22.31% to $12.6 million in 2022, then dropped by 21.88% to $9.9 million in 2023, then jumped by 44.25% to $14.2 million in 2024, then declined by 14.47% to $12.2 million in 2025.
- According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $12.2 million, $9.2 million, and $14.2 million for Q4 2025, Q1 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 12.17 Mn |
| Mar 31, 2025 | 9.24 Mn |
| Dec 31, 2024 | 14.23 Mn |
| Mar 31, 2024 | 3.65 Mn |
| Dec 31, 2023 | 9.86 Mn |
| Mar 31, 2023 | 3.06 Mn |
| Dec 31, 2022 | 12.63 Mn |
| Mar 31, 2022 | 5.52 Mn |
| Dec 31, 2021 | 16.25 Mn |